Marina Dorsch

Team Lead Global Technology Transfer (site-to-site Transfer) at Stada Group

Marina Dorsch has a diverse work experience in the pharmaceutical industry. Marina started their career as an intern at Rommelag Unternehmensgruppe in 2013 and later worked as a process development and validation specialist at ratiopharm in 2015. In 2016, they worked as a pharmacist at G+S Apotheke before transitioning to a role as a registered pharmacist at the same company in 2017. Marina then joined the University of Birmingham as a visiting research scientist in 2018. During the same year, they also worked as a product development project manager in R&D at Woerwag Pharma GmbH & Co. KG. Marina continued their pharmaceutical career at Schwanen Apotheke Stuttgart as a locum pharmacist from 2018 to 2023. In 2022, they became a team lead for technology transfer at STADA Group and in 2023, they started working as an apothecary at Struwwelpeter Apotheke. Marina Dorsch has extensive experience in various roles within the pharmaceutical industry, including management, research, and community pharmacy.

Marina Dorsch obtained their degree in Pharmazie from the University of Tübingen, where they studied from 2011 to 2016. Marina also holds additional certifications in various fields, including Process Scale-up, Validation & Technology Transfer and Microsoft Project Online. Marina obtained their Approbation als Apotheker certification from the Regierungspräsidium Stuttgart in 2016.

Location

Frankfurt, Germany

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Stada Group

14 followers

Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.


Industries

Employees

10,000+

Links